Global Infantile Spasms Therapeutics Market Growth (Status and Outlook) 2025-2031

Global Infantile Spasms Therapeutics Market Growth (Status and Outlook) 2025-2031

The global Infantile Spasms Therapeutics market size is predicted to grow from US$ 149 million in 2025 to US$ 186 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.

In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.

LPI (LP Information)' newest research report, the “Infantile Spasms Therapeutics Industry Forecast” looks at past sales and reviews total world Infantile Spasms Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Infantile Spasms Therapeutics sales for 2025 through 2031. With Infantile Spasms Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infantile Spasms Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Infantile Spasms Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Infantile Spasms Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infantile Spasms Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infantile Spasms Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infantile Spasms Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Infantile Spasms Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oral
Injection

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.